Early cessation of triptorelin in in vitro fertilization: A double-blind, randomized study

Simons, Arnold; Roelofs, H.J.M.; Schmoutziguer, A. P. E.; Roozenburg, Brigitte J.; Brink, Eefje P. van't Hof-van den; Schoonderwoerd, S. A.

doi:10.1016/j.fertnstert.2004.10.044

Cited by 14 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Faber et al (1998) were the first authors to present a beneficial effect of mid-luteal suppression with agonists on low response patients. Other studies compared pre-stimulation mid-luteal agonist with cases in which an agonist was continued throughout the follicular phase (Dirnfeld et al, 1999;Garcia-Velasco et al, 2000;Simons et al, 2005). Yet, there were no differences in the reproductive outcomes between the groups in a Cochrane review (Siristatidis et al, 2015).…”

Section: Discussionmentioning

confidence: 99%

Impact of pre-treatment in GnRH-antagonist cycles triggered with GnRH agonist on reproductive outcomes

Zivi,

Eldar-Geva,

Rubinstein

et al. 2023

JBRA

View full text Add to dashboard Cite

Objective Pre-treatment (PT) therapies in IVF are known to be used as pre-stimulation modality to improve cycle outcomes. This study aims to assess whether PT in GnRH antagonist cycles triggered with GnRH-agonist impact oocyte maturation response. Methods Data were retrospectively collected for patients who underwent GnRH antagonist cycle with agonist triggering with and without PT. The patients were allocated to groups according to their PT status. The primary outcome evaluated was suboptimal maturation response. Suboptimal maturation to trigger was defined as no oocyte upon retrieval when adequate response was expected. Results The study population included 196 patients who underwent GnRH antagonist cycle with agonist triggering. The study group included 69 patients who received PT. The control group included 127 patients with no PT. In univariate analysis, the PT group significantly displayed suboptimal response compared to the controls ( p = 0.008). All the patients in the study group with suboptimal response (with or without hCG re-triggering) were treated with GnRH-agonist as PT. Basal and pre-trigger LH values were significantly lower in the study group compared to controls ( p < 0.001). Multivariate regression analysis revealed that PT with GnRH agonist was a significant predictor for suboptimal response. Conclusions Pre-treatment, and particularly the use of GnRH-agonist as PT in antagonist cycles triggered with agonist, increases the risk of suboptimal response to GnRH-agonist trigger. This might be explained by prolonged pituitary suppression, which lasts beyond the PT cessation.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of pre-treatment in GnRH-antagonist cycles triggered with GnRH agonist on reproductive outcomes

Zivi,

Eldar-Geva,

Rubinstein

et al. 2023

JBRA

View full text Add to dashboard Cite

show abstract

“…Thirteen of these 21 articles stated that there were no serious adverse events reported, whereas the other 8 articles reported on a variety of maternal and fetal complications (6) (7) (8) (9) (10) (11) (12) (13) (Table 1). We found 30 other articles that although they did not specifically use the words “serious adverse event”, reported on death, hospitalization, congenital malformation, or in utero fetal demise (IUFD) (we searched specifically for these terms).…”

mentioning

confidence: 99%

Incomplete and inconsistent reporting of maternal and fetal outcomes in infertility treatment trials

Dapuzzo

Seitz

Dodson

et al. 2011

Fertility and Sterility

View full text Add to dashboard Cite

Pregnancy outcomes and adverse outcomes in infertility trials are reported to varying extents, e.g. 35% of clinical trials reported no information on pregnancy loss, only 43% reported adverse events during the preconception treatment period and only 7% reported any serious adverse events. Incomplete reporting limits the value of these studies in counseling patients on the risk/benefit ratio of treatment to themselves and their babies.

show abstract

Gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproductive treatment

Maheshwari¹,

Bhattacharya²,

Daya³

et al. 2008

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Early cessation of triptorelin in in vitro fertilization: A double-blind, randomized study

Cited by 14 publications

References 18 publications

Impact of pre-treatment in GnRH-antagonist cycles triggered with GnRH agonist on reproductive outcomes

Impact of pre-treatment in GnRH-antagonist cycles triggered with GnRH agonist on reproductive outcomes

Incomplete and inconsistent reporting of maternal and fetal outcomes in infertility treatment trials

Gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproductive treatment

Contact Info

Product

Resources

About